| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Evercore ISI Removes HPE From Tactical Outperform List, Keeps Long-Term Bull Case | ||
| Mo | Accenture and Palantir Form New AI Partnership to Accelerate Enterprise Transformation | ||
| Mo | IBM Leans on AI, Acquisitions, and Partnerships to Drive Growth | ||
| Mo | Microchip (MCHP) Target Up as Mizuho Turns Selective on Chips | ||
| Mo | Motorola Solutions (MSI) Upgrade Reflects Valuation Reset, Says Morgan Stanley Analyst | ||
| Mo | BMO Capital Raises AWS (AMZN) Growth Forecast as AI Demand and Claude Adoption Intensify | ||
| Mo | BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches | ||
| Mo | BMO Capital Boosts Google Cloud (GOOG) Outlook as Enterprise AI Adoption Hits Rapid Acceleration | ||
| Mo | BMO Capital Sees Impressive Guidance and Construction Cloud Momentum at Autodesk (ADSK) | ||
| Mo | Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential | ||
| Mo | BofA Trims Block (XYZ) PT After Consumer Finance Sector Review | ||
| Mo | Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 | ||
| Mo | Jim Cramer Says Darden (DRI)'s Olive Garden is the OG | ||
| Mo | Micron (MU)'s a "Gating Factor," Says Jim Cramer | ||
| Mo | Jim Cramer Discusses CoreWeave (CRWV)'s AI Data Center Buildout | ||
| Mo | Jim Cramer Says "Oracle (ORCL) is the Linchpin" | ||
| Mo | "We're Gonna See Seagate (STX) Go Up," Says Jim Cramer | ||
| Mo | "We're Gonna See Western Digital (WDC) Go Up," Says Jim Cramer | ||
| Mo | "I Was Very Impressed" by Medline (MDLN)'s IPO, Says Jim Cramer | ||
| Mo | "We're Gonna See Sandisk (SNDK) Go Up," Says Jim Cramer | ||
| Mo | Rivian (RIVN) Needs to Raise Money, Says Jim Cramer | ||
| Mo | Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) | ||
| Mo | Here is What Analysts Have to Say About Hinge Health (HNGE) | ||
| Mo | AI-Enabled Automation Driving Up Sentiment Towards Waystar (WAY) | ||
| Mo | Promising Growth Forecasts Leading to Analysts' Optimism for Procept Biorobotics (PRCT) |